Wall Street analysts expect that Cempra, Inc. (NASDAQ:MLNT) will report $2.48 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Cempra’s earnings. The lowest sales estimate is $880,000.00 and the highest is $4.55 million. Cempra posted sales of $3.97 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 37.5%. The firm is scheduled to announce its next quarterly earnings results on Thursday, December 7th.
According to Zacks, analysts expect that Cempra will report full year sales of $2.48 million for the current year, with estimates ranging from $7.50 million to $12.02 million. For the next fiscal year, analysts expect that the company will report sales of $41.67 million per share, with estimates ranging from $5.00 million to $93.69 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Cempra.
A number of analysts recently issued reports on MLNT shares. Jefferies Group reissued a “neutral” rating on shares of Cempra in a research report on Thursday, October 26th. Zacks Investment Research downgraded shares of Cempra from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Robert W. Baird raised shares of Cempra from an “underperform” rating to a “neutral” rating and set a $2.00 target price for the company in a research report on Wednesday, November 1st. ValuEngine raised shares of Cempra from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Finally, Ladenburg Thalmann Financial Services raised shares of Cempra from a “neutral” rating to a “buy” rating in a research report on Thursday, November 30th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Cempra currently has a consensus rating of “Hold” and an average target price of $6.05.
Cempra Company Profile
Melinta Therapeutics, Inc, formerly Cempra, Inc, is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Cempra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cempra Inc. and related companies.